Companies · Biotechnology

Cynvec LLC

NEW YORK · Biotechnology

Diligence memoA one-page analyst read on Cynvec LLC — recommendation, valuation, rhythm, risks.
$17.4M
Total raised · real
3
Rounds
7.9×
Latest step-up
Top 35%
Sector rank · raised
Series A
Latest stage · inferred · Sat Jul 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Cynvec LLC looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 2.57× the median modeled value of Series A Biotechnology companies in 2016–2018 (157 peers) — value vs value, same stage and era.
Dormant
  • Last raise 9.0 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Cynvec LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
17.3 yr record
Peak capital year was 2017 with $15.0M across 1 filings.
Market position
ahead of 66% of Biotechnology peers
Capital scale is ahead of 66% of Biotechnology peers; modeled value is above 84% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Needs review
Row-level filing totals differ from canonical totals, so amendment/superseded filtering should be checked.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2017: $15.0M across 1 filings.
  • Largest single filing was $15.0M on 2017-07-01.
  • Filing rows sum to $27.4M, while canonical raised total is $17.4M; likely amendments/superseded rows are mixed into the detail view.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
  • Canonical filtering should be tightened before using row-level totals for diligence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Cynvec LLC is one of 4293 Biotechnology companies tracked from NEW YORK. By capital raised it ranks mid-pack (ahead of 66% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BPre-Seed · 2009-03-09 Raised $500K (real) Modeled valuation $28M (est)$500K$28MPre-Seed2009Series A · 2015-07-01 Raised $10M (real) Modeled valuation $362M (est)$10M$362MSeries A2015Series A · 2015-10-17 Raised $1.9M (real) Modeled valuation $69M (est)$1.9M$69MSeries A2015Series A · 2017-07-01 Raised $15M (real) Modeled valuation $542M (est)$15M$542MSeries A2017+$10M+$1.9M+$15MCumulative $27M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$500K · 2009
Series A$10.0M · 2015no Seed on file
Series A extension$1.9M · 2015
Series A extension$15.0M · 2017

Stages are modeled from round size (public records carry no series label). No record for: Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$542.3M
Base estimate est.
$16.4M
Conservative case
$2.9B
Upside case
$68.2M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $27.6M · 2009-03-092009Series A · modeled $361.5M · 2015-07-01Series A · modeled $68.7M · 2015-10-17Series A · modeled $542.3M · 2017-07-012017
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
6.0 yr
Elapsed time used
9.0 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
33 mo
Avg between rounds
$2.1M/yr
Capital velocity
17.3 yr
On record since
2009
First round
4
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 2.4× above median
This company$17.4M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 2.8× above median
This company$15.0M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 8.5× above median
This company$542.3M
Sector median$64.2M

Raised more than 66% of sector peers (real $). Modeled value above 84% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #3 of 157.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0MCapital raised (log)Bio-Dent, LTD. LLC · Series A Raised $15.0M · modeled $542.3M (est)Anthera Pharmaceuticals Inc · Series A Raised $15.0M · modeled $542.3M (est)Biothera Holding Corp. · Series A Raised $16.2M · modeled $529.3M (est)Limelight Bio, Inc. · Series A Raised $14.0M · modeled $506.2M (est)Overture Life, Inc. · Series A Raised $13.6M · modeled $491.7M (est)TAI Diagnostics, Inc. · Series A Raised $21.1M · modeled $463.8M (est)Occulo Holdings LLC · Series A Raised $12.8M · modeled $462.7M (est)Agilis Biotherapeutics, Inc. · Series A Raised $25.7M · modeled $458.0M (est)CAMBRIDGE EPIGENETIX Ltd · Series A Raised $12.3M · modeled $444.4M (est)Genten Therapeutics, Inc. · Series A Raised $12.0M · modeled $433.8M (est)LTC BioSciences, Inc · Series A Raised $12.0M · modeled $433.8M (est)Cynvec LLC (this company) Raised $17.4M · modeled $542.3M (est)Cynvec LLC
CompanyStageRaised · realValue · estvs peer med.
Bio-Dent, LTD. LLCSeries A$15.0M$542.3M2.57×
Anthera Pharmaceuticals IncSeries A$15.0M$542.3M2.57×
Cynvec LLC this companySeries A$17.4M$542.3M2.57×
Biothera Holding Corp.Series A$16.2M$529.3M2.51×
Limelight Bio, Inc.Series A$14.0M$506.2M2.40×
Overture Life, Inc.Series A$13.6M$491.7M2.33×
TAI Diagnostics, Inc.Series A$21.1M$463.8M2.20×
Occulo Holdings LLCSeries A$12.8M$462.7M2.19×
Agilis Biotherapeutics, Inc.Series A$25.7M$458.0M2.17×
CAMBRIDGE EPIGENETIX LtdSeries A$12.3M$444.4M2.11×
Genten Therapeutics, Inc.Series A$12.0M$433.8M2.06×
LTC BioSciences, IncSeries A$12.0M$433.8M2.06×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$500K2009-03-09$2.8M$27.6M85%
Series A$10.0M2015-07-01$45.5M$361.5M85%
Series A$1.9M2015-10-17$8.6M$68.7M85%
Series A$15.0M2017-07-01$68.2M$542.3M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$500K2009-03-09
    • First recorded raise — entered as Pre-Seed.
    • 1 investor on this round.
  2. Series A$10.0M2015-07-01
    • Raised again after 76 mo — slower than the ~14 mo sector norm.
    • Round 20.0× larger than the prior — scaling up.
    • Switched to Rule 506(b) (was Rule 06).
  3. Series A$1.9M2015-10-17
    • Came back fast: 4 mo vs the ~14 mo sector norm.
    • Round 5.3× smaller than the prior — bridge or down round.
    • 3 investors on this round.
  4. Series A$15.0M2017-07-01
    • Raised 20 mo later, in step with the ~14 mo sector norm.
    • Round 7.9× larger than the prior — scaling up.
Intelligence
2020 ~Q2
Modeled next raise · ~33mo cadence
$45.0M
Modeled next size est.range $29.3M$72.0M
7.9×
Last step-up
$2.1M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Daniel O. Wilds1 other2015-07
Richard Purcell1 other2009-03
Carole Pittelman2017-07
Charles Dorego2015-07
Frank Stonebanks2009-03
Leonard Litwin2009-03
Robert Ivanhoe2009-03
Steve Blumenthal2015-07
Steven Blumenthal2009-03
Registry & provenance

Cynvec LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1385095
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Smart Pill CorpBiotechnologySeries A$17.5M$344.0Msame sector · same stage
Applied BioCode, Inc.BiotechnologySeries A$17.5M$334.6Msame sector · same stage
GestVision, Inc.BiotechnologySeries A$17.1M$361.5Msame sector · same stage
Foresight Biotherapeutics, Inc.BiotechnologySeries A$17.0M$542.3Msame sector · same stage
Neurologica CorpBiotechnologySeries A$17.0M$433.8Msame sector · same stage
Othera Pharmaceuticals, IncBiotechnologySeries A$18.0M$383.9Msame sector · same stage
Allele Biotechnology & Pharmaceuticals, Inc.BiotechnologySeries A$18.0M$397.7Msame sector · same stage
Kanyos Bio, Inc.BiotechnologySeries A$16.4M$376.0Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Cytek BioSciences, Inc.BiotechnologySeries D+$4.5B87%
CytoDyn Inc.BiotechnologySeries B$405.2M86%
Cytocom Inc.BiotechnologySeries A$167.5M86%
SiVEC Biotechnologies, Inc.BiotechnologySeed$8.4M86%
Ncalc, LlcBiotechnologyPre-Seed$33.1M86%
CyOmics, Inc.BiotechnologySeed$83.1M86%
CytoRecovery, Inc.BiotechnologySeed$30.5M86%
Cynaptec Pharmaceuticals, Inc.BiotechnologySeries A$21.7M85%
Frequently asked
How much funding has Cynvec LLC raised?
Cynvec LLC has raised approximately $17.4M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Cynvec LLC's estimated valuation?
Provath's modeled valuation for Cynvec LLC is approximately $542.3M (modeled range $16.4M–$2.9B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Cynvec LLC at?
Cynvec LLC's latest modeled financing stage is Series A. Its most recent recorded round closed around Sat Jul 01.
What does Cynvec LLC do and where is it based?
Cynvec LLC operates in the Biotechnology sector, based in NEW YORK.
Explore related

See where Cynvec LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Cynvec LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.